FAQ on Clene's Participation in the Canaccord Genuity 44th Annual Growth Conference
Summary
What is Clene Inc. known for?
Clene Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS, Parkinson’s disease, and multiple sclerosis.
What event is Clene participating in?
Clene is participating in the Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase, where it will present and host 1×1 investor meetings.
When is Clene’s presentation scheduled?
Clene’s presentation is scheduled for August 13, 2024, at 11:30 a.m. EST.
How can I view the live webcast of Clene’s presentation?
The live webcast can be viewed by visiting https://ibn.fm/uGo0W.
What is CNM-Au8(R)?
CNM-Au8(R) is an investigational first-in-class therapy developed by Clene that aims to improve central nervous system cells’ survival and function by targeting mitochondrial function and the NAD pathway while reducing oxidative stress.
Where is Clene based?
Clene is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland.
Where can I find more information about Clene?
More information about Clene can be found on their website at www.Clene.com.
Who can I contact for more information about Clene’s participation in the conference?
For more information, you can contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com or visit their website at https://www.InvestorBrandNetwork.com.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 132314